Clinical Trials Sponsored by Biowin

Total 1359 results

Biogen

Completed

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (Tysabri Japan)

Multiple Sclerosis

Japan
Biogen

Completed

A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers

Healthy

United States
Biogen

Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis

United States, Canada, Czech Republic, Hungary, Poland, Russian Federation, Slovakia
Biogen

Completed

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Multiple Sclerosis | Healthy

United States
Biogen

Completed

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Multiple Sclerosis

United States
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Biogen

Completed

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Biogen

Withdrawn

BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs (EMBRACE)

Rheumatoid Arthritis

Canada
Biogen

Completed

Avonex PEN Satisfaction and Patients Experience Clinical Trial (ASPECT)

Multiple Sclerosis

Canada
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Healthy Volunteers

Australia, China
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers (109HV108)

Healthy

Australia, China
Biogen

Completed

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Biogen

Completed

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Russian Federation
Biogen

Withdrawn

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis
Biogen

Terminated

Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors

Tumors

United States
Biogen

Completed

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Multiple Sclerosis

United States
Biogen

Completed

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Biogen

Completed

COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS (COMPASS)

Multiple Sclerosis, Relapsing-Remitting

Canada
Biogen

Terminated

A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle

Healthy

Canada
Biogen

Terminated

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States
Biogen

Completed

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)

Multiple Sclerosis

Denmark
Biogen

Completed

BIIB014 Cardiovascular Monitoring Study

Healthy

United States
Biogen

Terminated

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

Chronic Lymphocytic Leukemia

United States
Biogen

Completed

Avonex 15 Year Long Term Follow-up Study (15yASSURANCE)

Multiple Sclerosis

United States
Biogen

Completed

Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

Healthy
Biogen

Completed

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Completed

Open-Label Natalizumab Safety Extension Study

Multiple Sclerosis

United States
Biogen

Completed

Immunogenicity and Safety Study of Serum-Free Avonex

Multiple Sclerosis
Biogen

Terminated

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

B-Cell Chronic Lymphocytic Leukemia

United States
Biogen

Completed

Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease (MOBILE)

Parkinson's Disease

Poland, Israel, Serbia
Biogen

Completed

Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers

Healthy

United Kingdom
Biogen

Completed

AVONEX® Combination Trial - "ACT"

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
Bioven Europe

Terminated

Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients (EGF)

Carcinoma, Non-Small-Cell Lung

Philippines, Spain, United Kingdom, Malaysia, Georgia, Thailand, Germany, Bulgaria, Czechia, Poland, Romania
Biogen
Biogen Idec A/S

Completed

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis (ACTIMS)

Exercise

Sweden, Finland, New Zealand, Denmark, Norway, Australia
Bioven Europe

Terminated

A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients (NSCLC)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Biocon Biologics UK Ltd

Active, not recruiting

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis (DEVOTE)

Postmenopausal Women With Osteoporosis

United Kingdom
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of Choroideremia Study (NIGHT)

Choroideremia

Finland, United States, Canada, Denmark, Netherlands, Germany, United Kingdom, Brazil, France
BioVie Inc.

Completed

A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

Alzheimer Disease

United States
BioVie Inc.

Completed

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

Parkinson Disease

United States
Biogen
AbbVie

Terminated

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
NightstaRx Ltd, a Biogen Company

Enrolling by invitation

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (SOLSTICE)

Choroideremia | X-Linked Retinitis Pigmentosa

United States, United Kingdom, Netherlands, Germany, France, Brazil, Canada, Denmark, Finland
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS)

X-Linked Retinitis Pigmentosa

United States, France, United Kingdom, Finland, Netherlands, Germany, Canada
Biosion, Inc.

Recruiting

POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis (ADAMANT)

Atopic Dermatitis

United States
Biocon Limited

Completed

Efficacy and Safety of Itolizumab in COVID-19 Complications

Covid19 | Acute Respiratory Distress Syndrome | Cytokine Release Syndrome

India
Bioniz Therapeutics

Completed

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

LGL Leukemia | CTCL

United States
Biocon Limited

Completed

Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients

Type2 Diabetes Mellitus

India
Biogen
AbbVie

Terminated

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy, United States, Canada, Germany, Puerto Rico
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Biocon Limited

Completed

Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD

Type 2 Diabetes Mellitus

3

Subscribe